Find an Article

Filter articles

Showing 661 to 670 of 739 results

Courting controversy: the implications of Brüstle

EU, Germany16-10-2013

The Court of Justice of the European Union’s decision in the Brüstle case has worrying implications for some stem cell patents. Andy Sanderson looks at the landscape across Europe.

The priority trap: new disclosure requirements in Germany


A German Federal Court decision has given patent applicants in the life sciences field plenty to think about, as Wolfgang Bublak and Axel Berger explain.

AIPPI 2013: Pharmaceutical products and the trademark hiccup


The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products.

Big player: the Bavarian biotech cluster


With a track record of successful innovation, Munich is one of the leading lights of European biotech. LSIPR went to visit.

Teaching old drugs new tricks


Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach.

Biopharmaceuticals: can India have its cake and eat it?


There has been much debate about whether there is a global deterioration of IP, and many commentators would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India.

EPO decision could trip up US patent defenders


A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR.

Spiral Genetics: clarifying the gene pool


In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP.

Accelerating and decelerating patent prosecution in Europe and the UK

EU, UK31-07-2013Matt Smith and Jonathan Wills

At some offices, the passage of a patent through the system is not quite as fast as applicants might hope—and at others it may be quicker than they would like. Matt Smith and Jonathan Wills outline the situation.

Keeping secrets: protecting the smallpox vaccine


Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.

Showing 661 to 670 of 739 results